Mechanisms of Polyploidy and Aneuploidy in the Liver
Mechanisms of Polyploidy and Aneuploidy in the Liver
批准号:
8931964
负责人:
ANDREW W DUNCAN
金额:
$43.51万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-25 至 2019-06-30
关键词:
AffectAgeAmericanAneuploid CellsAneuploidyBiologyCause of DeathCell divisionCell physiologyCellsChromosome SegregationChromosomesChronicDataDevelopmentDiploidyDiseaseDisease ResistanceGene ExpressionGenesGenomeGoalsHealthHepaticHepatocyteHomeostasisHumanIndividualInjuryKnockout MiceLaboratoriesLifeLiverLiver DysfunctionLiver RegenerationLiver diseasesMammalsMeasuresMediatingMicroRNAsModelingMolecularMolecular ProfilingMusNatural regenerationNoduleOrganOrganismPhysiologicalPloidiesPolyploidyProcessResearchRoleSignal TransductionSteatohepatitisTestingTherapeuticTissue-Specific Gene ExpressionTyrosinemiasVariantViral hepatitisXenograft procedureYeastsbasebiological adaptation to stresscell typechronic liver diseasedifferential expressionimprovedinnovationinsightliver functionliver injuryliver repairmouse modelnovelpostnatalregenerativeresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Nearly 25 million Americans are affected by liver dysfunction, and liver diseases are the 10th leading cause of death in the US. There is a clear and urgent need for developing new alternatives to whole organ replacement. A better understanding of liver biology is required to improve existing approaches and to innovate therapies for the treatment of liver diseases, including viral hepatitis and steatohepatitis. Hepatocytes, the primary functional cell type in the liver, display a range of chromosomal diversity resulting from prevalent physiological polyploidy (>90% in mice and 50% in humans) and aneuploidy (60% in mice and 30-90% in humans). In eukaryotic organisms, cells usually contain a diploid genome comprised of pairs of homologous chromosomes. Polyploidy refers to gains in entire sets of chromosomes, and aneuploidy refers to gains and losses of individual chromosomes. The roles of hepatic polyploidy and aneuploidy represent a major gap in our current understanding of liver biology. We recently found that aneuploidy enhances the regenerative capacity of the mouse liver. In response to Tyrosinemia-induced injury, that is normally toxic to the liver, we identified a subset of aneuploid hepatocytes that was resistant to the disease. The data suggest that aneuploid hepatocytes are endowed with enhanced capacity for adaptation and regeneration. Our central hypothesis is that aneuploidy functions as an adaptive mechanism in response to hepatic injury. The goals of this application are to identify mechanisms regulating hepatic aneuploidy/polyploidy and to unravel how aneuploidy affects liver function. To investigate these questions, we propose in Specific Aim 1 to determine whether polyploid hepatocytes are necessary for development of aneuploid livers. Experiments will characterize hepatic cell divisions, karyotypes and stress response in E2f7/E2f8 knockout mice, which have normal liver function but are depleted of polyploid hepatocytes. In Specific Aim 2, we will dissect the role of a novel regulator of hepatic polyploidy, recently identified in ur laboratory, microRNA-122 (miR-122). Experiments will determine how miR-122 alters ploidy and aneuploidy throughout life. We will also identify cellular and molecular mechanisms by which miR-122 regulates hepatic ploidy. Finally, in Specific Aim 3, we will determine how random karyotypes (in aneuploid hepatocytes) affect function in the liver. We will utilize a novel xenotransplantation model to examine clonal nodules of regenerating human hepatocytes. Experiments will measure aneuploidy and determine gene expression profiles in these nodules. Together, these studies will define the extent to which aneuploidy affects liver repair/regeneration as well as the molecular mechanisms that control this process. Understanding how aneuploid hepatocytes arise and function will provide new and crucial insights into liver homeostasis, diseases and treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Polyploidy and Aneuploidy in the Liver
-
批准号:10548883
-
项目类别:
-
资助金额:$47.7万
-
财政年份:2014
-
负责人:ANDREW W DUNCAN
-
依托单位:
Mechanisms of Polyploidy and Aneuploidy in the Liver
-
批准号:10339419
-
项目类别:
-
资助金额:$47.41万
-
财政年份:2014
-
负责人:ANDREW W DUNCAN
-
依托单位:
Mechanisms of Polyploidy and Aneuploidy in the Liver
-
批准号:8796891
-
项目类别:
-
资助金额:$43.53万
-
财政年份:2014
-
负责人:ANDREW W DUNCAN
-
依托单位:
Mechanisms of In Vivo Cell Fusion
-
批准号:7260424
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2006
-
负责人:ANDREW W DUNCAN
-
依托单位:
Mechanisms of In Vivo Cell Fusion
-
批准号:7450731
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:ANDREW W DUNCAN
-
依托单位:
Mechanisms of In Vivo Cell Fusion
-
批准号:7153761
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2006
-
负责人:ANDREW W DUNCAN
-
依托单位:
Cellular Approaches to Tissue Engineering and Regeneration
-
批准号:10663265
-
项目类别:
-
资助金额:$21.1万
-
财政年份:2003
-
负责人:ANDREW W DUNCAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: